{"id":4268,"date":"2026-11-12T09:00:00","date_gmt":"2026-11-12T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4268"},"modified":"2026-11-12T20:57:34","modified_gmt":"2026-11-13T00:57:34","slug":"vor-adds-remegen-rc298-to-autoimmune-license","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4268","title":{"rendered":"Vor Adds RemeGen RC298 to Autoimmune License"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Vor_RemeGen_Deal_and_Financing-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4271\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Vor_RemeGen_Deal_and_Financing-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Vor_RemeGen_Deal_and_Financing-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Vor_RemeGen_Deal_and_Financing-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Vor_RemeGen_Deal_and_Financing-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261112_Vor_RemeGen_Deal_and_Financing.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Vor Bio; RemeGen<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>License amendment<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Engineered TACI-Fc fusion protein (long-acting)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>RC298<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>BAFF; APRIL<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Autoimmune disease<\/p>\n<h4>Summary<\/h4>\n<p>Vor Bio and China-based RemeGen amended their existing telitacicept license on November 12 to add RC298, a preclinical long-acting BAFF\/APRIL inhibitor, for exclusive development and commercialization outside Greater China.<\/p>\n<p>The filed terms specify $10 million cash upfront plus warrants for 2.3 million Vor shares valued at about $46 million using the November 11 closing price; the warrant value is equity consideration, not cash. Up to $300 million in development milestones may follow, with existing sales-milestone and royalty terms applying across products. RemeGen retains Greater China rights and leads preclinical and Phase 1 development; Vor takes subsequent ex-China development. China IND filing is anticipated in first-half 2027.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> the amendment may extend an autoimmune franchise beyond telitacicept with longer dosing intervals. Support: shared BAFF\/APRIL biology and nonclinical PK claims. Against: RC298 has no human efficacy or tolerability evidence.<\/p>\n<p><strong>Interpretation B:<\/strong> a China-first handoff and equity-heavy consideration may defer ex-China development risk. Support: staged responsibilities and contingent value. Against: a partner with existing program knowledge could execute efficiently. Watch China IND acceptance, human PK\/PD, anti-drug antibodies, infection and hypogammaglobulinemia, global bridging, manufacturing transfer and warrant dilution. A failed human exposure advantage would weaken the differentiation thesis.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>RC298 is an engineered TACI-Fc fusion protein binding BAFF and APRIL to reduce pathogenic B-cell and plasma-cell survival in autoimmune disease. Telitacicept is the related earlier asset in the Vor\u2013RemeGen arrangement.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: company SEC exhibit and Chinese exchange-origin notice align on rights and economic structure.<\/li>\n<li>Missing: royalty rates, exact potency comparisons, clinical protocol and cash-flow timing.<\/li>\n<li>Preclinical superiority is a company claim.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A material cross-border franchise expansion, with modest cash relative to the headline consideration. Its value depends on human differentiation and a clean China-to-global transfer, not a stated best-in-class ambition.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: high. Confidence in Interpretation: moderate-low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vor Bio and China-based RemeGen amended their existing telitacicept license on November 12 to add RC298, a preclinical long-acting BAFF\/APRIL inhibitor, for exclusive development and commercialization outside Greater China.<\/p>\n","protected":false},"author":1,"featured_media":4271,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1473,1472,1471],"class_list":["post-4268","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-rc298","tag-remegen","tag-vor-bio"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4268"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4268\/revisions"}],"predecessor-version":[{"id":4295,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4268\/revisions\/4295"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4271"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}